ARQT Arcutis Biotherapeutics, Inc.
Price Chart
Executive Summary
Arcutis Biotherapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders, where all three proposals were approved, including the election of three Class III directors, ratification of Ernst & Young as independent auditor, and non-binding advisory approval of executive compensation. Separately, the Board approved an amended and restated Non-Employee Director Compensation Program, effective June 5, 2026, which sets annual cash retainers (e.g., $50,000 base for non-employee directors) and equity awards (initial option up to $350,000 grant date fair value, annual awards of ~$350,000 split 65% options / 35% RSUs). This is a routine governance filing with no material financial impact.
Actionable Insight
No trading action warranted. This is a routine annual meeting and director compensation update with no earnings, guidance, or operational news. Monitor next quarterly earnings for commercial progress of ZORYVE and pipeline updates.
Key Facts
- All three proposals at the 2026 Annual Meeting were approved by stockholders.
- Three Class III directors elected: Patrick J. Heron, Neha Krishnamohan, Todd Franklin Watanabe.
- Ratification of Ernst & Young LLP as independent auditor for fiscal year 2026 approved (107,867,442 for, 15,748 against, 261,364 abstentions).
- Non-binding advisory approval of named executive officer compensation passed (88,728,269 for, 3,723,408 against, 824,860 abstentions, 14,868,017 broker non-votes).
- Board approved Amended and Restated Non-Employee Director Compensation Program effective June 5, 2026.
- Annual cash retainer for non-employee directors: $50,000; additional $40,000 for Non-Executive Chair.
- Annual equity award grant date fair value approximately $350,000 per director (65% options, 35% RSUs).
- Initial option grant for new directors: up to $350,000 grant date fair value, vesting over three years.
Financial Impact
No material financial impact. Director compensation changes are routine and within standard ranges for a $2.7B market cap biotech.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-041883 |
| Exhibit: exhibit101amendedandrestat.htm | 0001628280-26-041883 |
| Document: 0001628280-26-041883-index-headers.html | 0001628280-26-041883 |
| Document: 0001628280-26-041883-index.html | 0001628280-26-041883 |
| Document: 0001628280-26-041883.txt | 0001628280-26-041883 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
5d ago
|
8-K
| $22.78 awaiting T+5 | awaiting T+5 | — | $24.38 (+7.02%) |
|
May 11, 2026
4w ago
|
144
| $20.69 $20.03 | ▼ −3.19% | ▼ −3.27% | $24.38 (+17.83%) |
|
May 6, 2026
5w ago
|
Press Release
| $20.66 $21.69 | ▲ +4.99% | ▲ +3.48% | $24.38 (+18.01%) |
|
May 4, 2026
6w ago
|
Insider Cluster
| $23.49 $21.24 | ▼ −9.58% | ▼ −12.51% | $24.38 (+3.79%) |
|
May 1, 2026
6w ago
|
Insider Cluster
| $23.35 $20.66 | ▼ −11.52% | ▼ −13.87% | $24.38 (+4.41%) |
|
Apr 15, 2026
8w ago
|
Press Release
| $24.19 $22.86 | ▼ −5.50% | ▼ −6.48% | $24.38 (+0.79%) |
|
Mar 2, 2026
15w ago
|
Insider Cluster
| $24.76 $24.82 | ▼ −0.24% | ▼ −1.45% | $24.38 (+1.53%) |
|
Mar 2, 2026
15w ago
|
Insider Cluster
| $24.76 $24.82 | ▲ +0.24% | ▲ +1.45% | $24.38 (−1.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access